Traditional Chinese medicine polysaccharide in nano-drug delivery systems: Current progress and future perspectives

Wang, Juan; Wu, Xia; Chen, Jing; Gao, Ting; Zhang, Yumei; Yu, Na

doi:10.1016/j.biopha.2024.116330

Cited by 4 publications

(1 citation statement)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral polysaccharides are not only directly intestinally absorbed and distributed to target organs, but also exert their activities by entering PPs or/and modulating the gut microbiota and their metabolites, which is a breakthrough in explaining the quantitative-effect relationship of polysaccharides ( Zhang et al, 2022 ). In order to solve the problem of low oral bioavailability of polysaccharides, researchers are committed to constructing oral drug delivery systems based on natural polysaccharides ( Li et al, 2017 ; Zheng et al, 2022a ), such as liposomes, conjugates, in situ formation systems, and nanoparticles, which show promising results in improving polysaccharides delivery across the biological barriers and prolonging the cycling time of their targeted delivery, and are expected to provide support for the clinical application of natural polysaccharides ( Wang et al, 2024 ).…”

Section: Resultsmentioning

confidence: 99%

In vivo pharmacokinetics of Glycyrrhiza uralensis polysaccharides

Wubuli,

Chai,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Glycyrrhiza uralensis polysaccharides (GUPS) are widely applied in biomedicine and functional food due to their multiple pharmacological activities and low toxicity. Despite their widespread use, the in vivo metabolic profile of GUPS remains poorly understood. To address this gap, we developed a quantitative analysis method that involves labeling GUPS with visible fluorescein (5-DTAF) and near-infrared (NIR) fluorescein (Cy7), resulting in stable conjugates with substitution degrees of 0.81% for 5-DTAF and 0.39% for Cy7. The pharmacokinetic studies showed a biphasic elimination pattern in the blood concentration-time curve following both intravenous and oral administration, consistent with a two-compartment model. Using fluorescence quantification and NIR imaging, we observed that GUPS was distributed to various tissues, exhibiting higher concentrations particularly in liver, kidney and lung. Excretion studies indicated that feces were the major excretion pathway of GUPS after oral administration (60.98%), whereas urine was the main pathway after intravenous administration (31.16%). Notably, GUPS could be absorbed rapidly by gut (Tmax 1 ± 0.61 h) and showed a biological half-time t1/2 26.4 ± 7.72 h after oral administration. Furthermore, the Caco-2 cells uptake studies illustrated that macropinocytosis and clathrin-mediated endocytosis were participated in the transport of GUPS in intestine epithelium. This comprehensive analysis of the in vivo pharmacokinetics of GUPS not only enhances our understanding of its metabolic pathways but also establishes a foundational basis for its clinical application, optimizing its therapeutic potential and safety profile.

show abstract